Evidence map›Paper›PMID 29349603›Full record

ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2018

Neoadjuvant chemoradiation for esophageal cancer : Surgery improves locoregional control while response based on FDG-PET/CT predicts survival.

Nina-Sophie Hegemann, Rebecca Koepple, Franziska Walter, David Boeckle, Wolfgang P Fendler, Martin Kurt Angele, Stefan Boeck, Claus Belka, Falk Roeder

Abstract read
PubMed Publisher
In one paragraph

Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Radiochemotherapy with or without cetuximab for unresectable esophageal cancer: final results of a randomized phase 2 trial (LEOPARD-2).Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2020
    Trial
  2. Article
  3. Neoadjuvant versus definitive radiochemotherapy of locoregionally advanced oesophageal cancer-who benefits?Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2022
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nina-Sophie HegemannDepartment of Radiation Oncology, University of Munich (LMU), Marchioninistr. 15, 81377, Munich, Germany. Nina-Sophie.Hegemann@med.uni-muenchen.de.ORCID 0000-0002-2091-3603
Rebecca KoeppleDepartment of Radiation Oncology, University of Munich (LMU), Marchioninistr. 15, 81377, Munich, Germany.
Franziska WalterDepartment of Radiation Oncology, University of Munich (LMU), Marchioninistr. 15, 81377, Munich, Germany.
David BoeckleDepartment of Radiation Oncology, University of Munich (LMU), Marchioninistr. 15, 81377, Munich, Germany.
Wolfgang P FendlerDepartment of Nuclear Medicine, University of Munich (LMU), Munich, Germany.
Martin Kurt AngeleDepartment of General, Visceral, Transplantation, Vascular and Thoracic Surgery, University of Munich (LMU), Munich, Germany.
Stefan BoeckDepartment of Internal Medicine III-Medical Oncology, University of Munich (LMU), Munich, Germany.
Claus BelkaDepartment of Radiation Oncology, University of Munich (LMU), Marchioninistr. 15, 81377, Munich, Germany.
Falk RoederDepartment of Radiation Oncology, University of Munich (LMU), Marchioninistr. 15, 81377, Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTo retrospectively analyze the outcome of patients with esophageal cancer treated with neoadjuvant chemoradiation.

methodsA total of 41 patients received neoadjuvant intent chemoradiation for esophageal cancer. Most patients had a locally advanced disease (T3/4: 82%, N+: 83%, M0: 100%) and squamous cell carcinoma (83%). All patients received concurrent chemotherapy with cisplatin/5-fluorouracil or mitomycin/5-fluorouracil. Median radiation dose was 50.4 Gy in the 25 patients who proceeded to surgery and 57.4 Gy in 16 patients who did not undergo surgery. FDG-PET/CT was used for treatment planning in 24 patients. A second FDG-PET/CT was available for response evaluation in 18 patients.

resultsMedian follow-up was 16 months in all patients and 30 months in survivors. Radiotherapy was completed without interruptions >3 days in 90% of patients, and chemotherapy was carried out to >80% in 85% of patients. The 2‑year locoregional control rate was 60%, distant control rate 54% and overall survival rate 50%. Hematological toxicity grade 3/4 was observed in 34%/10% of patients and non-hematological toxicity grade 3/4 in 46%/2% of patients. Perioperative 30-day mortality was 4%. Subgroup analyses revealed that surgery significantly improved locoregional control (74% vs. 39%, p = 0.034), but not the 2‑year survival rate (54% vs. 43%, p = 0.246). In contrast, response based on FDG-PET/CT prior and after chemoradiation significantly predicted improved overall survival (2-year overall survival 61% vs. 40%, p = 0.048).

conclusionOutcomes of our cohort were comparable to other series using similar treatments. Surgery significantly improved locoregional control but not survival. Response based on FDG-PET/CT predicted survival and might be used for treatment stratification.

Indexed as

EsophagectomyFluorodeoxyglucose F18AdultAgedChemoradiotherapy, AdjuvantCombined Modality TherapyEsophageal NeoplasmsFemaleHumansMaleMiddle AgedNeoadjuvant TherapyNeoplasm StagingPositron Emission Tomography Computed TomographyFluorodeoxyglucose F1818F-FDG PET/CTChemoradiationEsophagus cancerNeoadjuvantSurgery

Identifiers

PMID29349603

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.